갑상선 종양에서 VEGF(Vascular Endothelial Growth Factor)의 발현과 신생혈관생성

Expression of Vascular Endothelial Growth Factor and Angiogenesis in the Thyroid Tumor

  • 태경 (한양대학교 의과대학 이비인후과학교실) ;
  • 이용섭 (한양대학교 의과대학 이비인후과학교실) ;
  • 박인범 (한양대학교 의과대학 이비인후과학교실) ;
  • 서인석 (한양대학교 의과대학 이비인후과학교실) ;
  • 이형석 (한양대학교 의과대학 이비인후과학교실) ;
  • 오영하 (한양대학교 의과대학 병리학교실) ;
  • 박용수 (한양대학교 의과대학 내과학교실) ;
  • 안유헌 (한양대학교 의과대학 내과학교실)
  • Tae Kyung (Department of Otolaryngology-Head and Neck Surgery, University of Hanyang College of Medicine) ;
  • Lee Yong-Seop (Department of Otolaryngology-Head and Neck Surgery, University of Hanyang College of Medicine) ;
  • Park In-Beom (Department of Otolaryngology-Head and Neck Surgery, University of Hanyang College of Medicine) ;
  • Seo In-Seok (Department of Otolaryngology-Head and Neck Surgery, University of Hanyang College of Medicine) ;
  • Lee Hyung-Seok (Department of Otolaryngology-Head and Neck Surgery, University of Hanyang College of Medicine) ;
  • Oh Young-Ha (Department of Pathology, University of Hanyang College of Medicine) ;
  • Park Yong-Soo (Department of Internal Medicine, University of Hanyang College of Medicine) ;
  • Ahn Yoo-Heon (Department of Internal Medicine, University of Hanyang College of Medicine)
  • 발행 : 2004.11.01

초록

Background and Objectives: Angiogenesis is the process of new blood vessel development from preexisting vessel. Angiogenenesis has been considered to be essential for the growth and expansion of a solid tumor. Vascular endothelial growth factor (VEGF), known as one of the most important vascular permeability factors, induces proliferation of endothelial cells, stiumulates angiogenesis, and increases vascular permeability. Several recents reports have documented that VEGF overexpression is associated with poor clinical outcomes in many maligmancies. The aims of this study were to determine whether microvessel density and VEGF expression are related to clinicopathologic factors such as age, sex, tumor size, tumor stage, and prognostic factors and to evaluate the relationship between VEGF expression and angiogenesis in benign and malignant thyroid tumors. Materials and Methods: The subjects were 65 patients (27 with papillary carcinoma, 27 with adenomatous hyperplasia, 11 with follicular adenoma) who underwent thyroidectomy from 1995 to 2001. Imuunohistochemistry was used to detect VEGF expression and microvessel density (MVD) in paraffin-embedded thryoid tumor specimens. Results: The intensity of the VEGF expression did not show stastically difference between benign and malignant thyroid tumors. There was no apparent correlation between VEGF expression and age, tumor size, T stage or scores of the AGES, AMES and MACIS systems. The neo-microvessel density was higher in the maligant tumor than the benign tumors. Also, higher neo-microvessel density was associated with metastases of the lymph nodes and scores of the AMES and AGES systems. Conclusion: Our results suggest that neo-microvessel vessel density may be a significant prognostic factor in the thyroid papillary carcinoma. But the VEGF expression does not appear to be an significant independent prognostic factor for thyroid papillary carcinoma.

키워드

참고문헌

  1. Folkman J: Angiogenesis in cancer; vascular; rheumatoid, and other disease. Nat Med. 1995;1:27-31 https://doi.org/10.1038/nm0195-27
  2. Folkman J: Role ofangiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18
  3. Brown LF, Berse B, Jackman RW, et al: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255-1262
  4. Stravri GT, Zachary IC, Baskerville PA: Basic fibroblast growth factor upregulations the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation. 1995;92:11
  5. Vincenti V, Cassano C, Rocchi M, Persico G: Assignment of the vascular endothelial growth factor gene to the human chromosome 6p21.3. Circulation. 1996;93:1493-1495
  6. Brock TA, Dvorak HF, Senger DR: Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Villebrand factor release in human endothelial cells. Am J Pathol. 1991;128:213-221
  7. Guidi AJ, Abu-Jawdeh G, Berse B, et al: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst.1995;87:1237-1245 https://doi.org/10.1093/jnci/87.16.1237
  8. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8 https://doi.org/10.1056/NEJM199101033240101
  9. Macchiarini P, Fontanini G, Hardin M, Squartini F, Angeletti CA: Realtion of neovascularization to metastasis of non-smallcell lung cancer. Lancet 1991;340:145-146 https://doi.org/10.1016/0140-6736(92)93217-B
  10. Viglietto G, Maglione D, Cerutti J, et al: Upregulation ofvascular endothelial growth factor (vEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid and cell lines. Oncogene. 1995;11:1569-1579
  11. Soh EY, Dub QY, Sobhi SA, et al: Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997;82:3741-3747 https://doi.org/10.1210/jc.82.11.3741
  12. Michelel R, Susan D, Prudence AES, Stephen F, Kenneth S, Russell L: Expression of the angiogenetic factor. Vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor $\beta$-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963-969
  13. FolkmanJ: Role ofangiogenesis in tumor growth and metastasis. Smin Oncol. 2002;29:15-18
  14. Maeda K, Chung YS, Ogawa Y: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer.1996;77:858-863 https://doi.org/10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A
  15. Abu-Jawdeh G, Faix J, Niloff J, et al: Strong expression of vascular perveability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and mailgnant neoplasms. Lab Invest. 1996;74:1105-1115
  16. Enisma RJ, Spiro JD, Kreuzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg. 1997;174:513-517 https://doi.org/10.1016/S0002-9610(97)00166-9
  17. Kilicarslan AB, Ogus M, Arid C, Pestereli HE, Cakir M, Karpuzoglu G: Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS. 2003;111:439-443 https://doi.org/10.1034/j.1600-0463.2003.t01-1-1110209.x
  18. Huang SM, Lee JC, Wu TJ, Chow NH: Clinical relevance of vascular endothelial growth factor thyroid neoplasms. World J Surg. 2001;25:302-306 https://doi.org/10.1007/s002680020085
  19. Katoh R, Miyagi E, Kawaoi A, et al: Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum PathoI. 1999;30:891-897 https://doi.org/10.1016/S0046-8177(99)90241-1
  20. Klein M, Picard E, Vignaud JM, et al: Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999;161:41-49 https://doi.org/10.1677/joe.0.1610041